텍토닉 테라퓨틱(TECX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $27.28 (+0.26%), 시가총액 $0.52B, 52주 최저~최고 $14.71 ~ $35.87.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
텍토닉 테라퓨틱의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
텍토닉 테라퓨틱의 현재 주가는 $27.28 (+0.26%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
텍토닉 테라퓨틱의 시가총액은 약 $0.52B입니다.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It